Cite
730-P: Basal Insulin Regimen vs. Twice-Daily Premix Insulin Regimen after Short-Term Intensive Insulin Therapy (SIT) in Patients with Type 2 Diabetes (T2D): A Multicenter, Open-Label Randomized Controlled Trial.
MLA
Mu, Yiming, et al. “730-P: Basal Insulin Regimen vs. Twice-Daily Premix Insulin Regimen after Short-Term Intensive Insulin Therapy (SIT) in Patients with Type 2 Diabetes (T2D): A Multicenter, Open-Label Randomized Controlled Trial.” Diabetes, vol. 70, June 2021, p. N.PAG. EBSCOhost, https://doi.org/10.2337/db21-730-P.
APA
Mu, Y., Guo, L., Wan, H., Wang, J., Xu, B., Wang, G., Jiang, C., Liang, L., Feng, W., Liu, J., Zhang, X., Cui, N., & Yin, H. (2021). 730-P: Basal Insulin Regimen vs. Twice-Daily Premix Insulin Regimen after Short-Term Intensive Insulin Therapy (SIT) in Patients with Type 2 Diabetes (T2D): A Multicenter, Open-Label Randomized Controlled Trial. Diabetes, 70, N.PAG. https://doi.org/10.2337/db21-730-P
Chicago
Mu, Yiming, Lixin Guo, Hailong Wan, Junfen Wang, Binhua Xu, Guoping Wang, Chengxia Jiang, et al. 2021. “730-P: Basal Insulin Regimen vs. Twice-Daily Premix Insulin Regimen after Short-Term Intensive Insulin Therapy (SIT) in Patients with Type 2 Diabetes (T2D): A Multicenter, Open-Label Randomized Controlled Trial.” Diabetes 70 (June): N.PAG. doi:10.2337/db21-730-P.